We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-38.00 | -0.32% | 11,988.00 | 12,014.00 | 12,018.00 | 12,144.00 | 11,882.00 | 12,070.00 | 2,340,814 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.28 | 186.27B |
By Jaime Llinares Taboada
AstraZeneca PLC said Friday that trials to study the combination of the tremelimumab monoclonal antibody and Imfinzi demonstrated overall survival benefit for patients with liver cancer.
Ghassan Abou-Alfa, the principal investigator in the trial, said the combination of these antibodies boosts the patient's immune system against liver cancer, aiming to maximize long-term survival with minimal side effects.
This Phase 3 trial involved 1,324 patients in 16 countries and compared the tremelimumab-Imfinzi therapy against sorafenib, a standard-of-care multi-kinase inhibitor.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
October 15, 2021 02:34 ET (06:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions